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Rapid biodosimetry tools are required to assist with triage
in the case of a large-scale radiation incident. Here, we aimed
to determine the dose-assessment accuracy of the well-
established dicentric chromosome assay (DCA) and cytoki-
nesis-block micronucleus assay (CBMN) in comparison to the
emerging c-H2AX foci and gene expression assays for triage
mode biodosimetry and radiation injury assessment. Coded
blood samples exposed to 10 X-ray doses (240 kVp, 1 Gy/min)
of up to 6.4 Gy were sent to participants for dose estimation.
Report times were documented for each laboratory and
assay. The mean absolute difference (MAD) of estimated
doses relative to the true doses was calculated. We also
merged doses into binary dose categories of clinical relevance
and examined accuracy, sensitivity and specificity of the
assays. Dose estimates were reported by the first laboratories
within 0.3–0.4 days of receipt of samples for the c-H2AX and
gene expression assays compared to 2.4 and 4 days for the
DCA and CBMN assays, respectively. Irrespective of the
assay we found a 2.5–4-fold variation of interlaboratory
accuracy per assay and lowest MAD values for the DCA
assay (0.16 Gy) followed by CBMN (0.34 Gy), gene expression
(0.34 Gy) and c-H2AX (0.45 Gy) foci assay. Binary categories
of dose estimates could be discriminated with equal efficiency
for all assays, but at doses 1.5 Gy a 10% decrease in
efficiency was observed for the foci assay, which was still
comparable to the CBMN assay. In conclusion, the DCA has
been confirmed as the gold standard biodosimetry method,
but in situations where speed and throughput are more
important than ultimate accuracy, the emerging rapid
molecular assays have the potential to become useful triage
tools.  2013 by Radiation Research Society
INTRODUCTION
Whenever a person may have been exposed to significant
levels of ionizing radiation, it is important to estimate the
dose received to determine any short- or long-term health
implications and provide the evidence base for counseling.
Such overexposure cases are typically rare and involve only
one or a few potential casualties. The main focus for such
isolated cases is to provide the most accurate dose estimate,
taking into account exposure characteristics such as
radiation type and quality as well as uniformity, duration
and timing of the exposure (1, 2).
The dicentric chromosome assay (DCA) and the cytoki-
nesis-block micronucleus assay (CBMN) have been estab-
lished as the main biodosimetry tests for ionizing radiation
exposure (3). These two cytogenetic methods combine high
(DCA) or reasonable (CBMN) specificity, sensitivity of the
order of 100 mGy and persistence of the signal for several
months. Dozens of laboratories around the world have
established calibration curves that enable chromosome
aberration yields to be converted to dose estimates, and
the quantitative impact of the specific exposure character-
istics listed above on aberration yields and distributions has
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been assessed in great detail and implemented in the
methodology for radiation dose estimation. Sample prepa-
ration and data analysis procedures have been harmonized
(3) and standardized for the DCA (4), ensuring consistency
between laboratories.
In contrast to the typical scenario of a radiation incident
that affects only a few individuals, rapid tools are required
in the case of large-scale accidental exposure or deliberate
radiation exposure to (1) help identify the few severely
exposed individuals who may require clinical monitoring
and treatment and (2) reassure the many ‘‘worried-well’’, to
prevent them from overwhelming emergency responders
and healthcare infrastructure (5, 6). Therefore, the focus
shifts with increasing number of potential casualties from
utmost accuracy, sensitivity and specificity to large capacity
and rapid delivery of test results. Consequently, the
characteristics of the ideal biodosimeter for rapid triage
differ significantly from those for individual dose assess-
ment and pose major challenges for the cytogenetic assays
with their slow turn-around times and low throughput.
Several different approaches have been or are currently
being implemented to address the capacity gap: triage mode
scoring for the dicentric assay (7, 8), ‘‘QuickScan’’ dicentric
chromosome analysis (9), networking between biodosim-
etry laboratories (10–16), telescoring (17), automation (18,
19) and the development of novel assays that have the
potential for quicker reporting times and higher throughput
than the established cytogenetic methods (1, 2). These novel
assays include gene expression analysis (e.g., 20, 21) and
the c-H2AX foci assay (22), two methods that enable the
analysis of interphase cells and thus avoid the two- to three-
day incubation steps necessary for the DCA and CBMN
assays. Furthermore, sample preparation and analysis for
these molecular endpoints are more amenable to parallel
processing and automation, enabling larger capacity.
However, while the cytogenetic assays quantify the end
products of DNA double-strand break misrepair (23), which
persist in a nondividing lymphocyte, the gene expression
and foci assays measure intermediate signals formed in
irradiated cells which change rapidly over time: transcrip-
tional responses to radiation damage and DNA double-
strand breaks, most of which are repaired within a day after
exposure. These characteristics may cause larger signal
variability (and therefore dose uncertainty) and likely
restrict the window of opportunity for these assays to a
few days post exposure. Given the emphasis on rapid triage
in a large-scale incident, these disadvantages may still be
acceptable, especially when considering a two-tiered system
where initial triage using one of these molecular assays is
followed by more accurate chromosome dosimetry for those
identified as highly exposed.
Intercomparison exercises using ex vivo irradiated coded
samples are an important tool for validating the perfor-
mance of assays as well as laboratories. They have gained
even more relevance with the increasing role of interna-
tional networking and the search for new rapid biomarkers
for radiation exposure. Most intercomparisons reported so
far have tested the proficiency of participating laboratories
in using one specific well established assay for estimating
doses for a small number of samples with no time pressure
(e.g., 13–16). Here, we have added several dimensions by
(1) comparing established (DCA, CBMN) as well
emerging assays (gene expression, c-H2AX foci) and
one assay (H-module) dealing with estimates of hemato-
logical damage and not exposure (dose estimate), (2)
allowing for both manual and automated scoring, (3)
testing how the number of scored cells affects dose
estimates and (4) by timing the delivery of dose estimates.
In addition to the intra-assay (interlaboratory) comparisons
for individual biodosimetry assays described in our four
companion articles. This design has allowed us to directly
compare the two most important characteristics relevant
for decision making regarding diagnosis and therapy in a
large-scale incident, accuracy and speed, for the four
different assays (inter-assay comparison). The findings of
this comparison are presented in this article, together with
an assessment of the assays’ ability to discriminate
between binary dose categories representing clinically
relevant treatment groups of potentially overexposed
individuals. In particular this approach was introduced to
attempt to bridge the gap between dose estimates and
medical decision making.
This NATO exercise was organized under the umbrella of
the NATO Research Task Group RTG-033 ‘‘Radiation
Bioeffects and Countermeasures’’ (24). It was limited to ex
vivo uniformly irradiated blood to simulate acute whole
body exposure. Given the low level of ‘‘technological
readiness’’ of the emerging assays we decided not to
enforce harmonization of assay procedures across partici-
pating laboratories but instead invited partners to use each
assay in the format it was established in the individual
laboratory. The level of proficiency of the assay format and
laboratory would be reflected in the accuracy and reporting
time of dose or radiation injury estimates for the unknown
samples.
MATERIALS AND METHODS
Blood Sampling, Radiation Exposure and Distribution to Participants
Peripheral blood was drawn from one healthy human volunteer (29-
year-old male) and aliquots of 2–3 ml whole blood filled into
heparinized vials using a vacutainer system (Becton Dickinson,
Germany). Blood was taken with informed consent and the approval
of a local ethics committee. Blood samples exposed to known
radiation doses were initially provided to participants for the optional
generation of calibration data in the respective laboratory using the
same radiation quality and irradiation conditions as for the blind
samples. Two months later, ten coded blood samples were distributed
to participating laboratories for rapid biodosimetry. Fresh blood
samples were irradiated at 378C using single doses of X rays with a
mean photon energy of 100 keV (240 kVp; X-ray tube type MB 350/1
in Isovolt 320/10 protection box; Agfa NDT Pantak Seifert GmbH &
Co.KG, Ahrensburg, Germany) filtered with 7.0 mm beryllium and
2.0 mm aluminum. The absorbed dose was measured using a duplex
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dosimeter (PTW, Freiburg, Germany). The dose-rate was approxi-
mately 1.0 Gy min1 at 13 mA. Applied doses for calibration curve
production ranged from 0.25–5 Gy, whereas doses for blind samples
ranged from 0.1–6.4 Gy. After irradiation, samples were incubated at
378C for a certain period of time and shipped by overnight courier
service under defined conditions according to United Nation
Regulation 650. Temperature profiles and potential radiation expo-
sures were monitored by adding temperature loggers (TL30, 3M,
Neuss, Germany) and film badges (Helmholtz Zentrum Munich,
Germany) to the packages.
Sample Processing and Analysis for the Different Biodosimetry Assays
Protocols for sample preparations and analysis for the four
biodosimetry assays are described in the four companion articles of
this series.
Collection of Biodosimetry Data and Survey Information
Two data sheets were provided, one to rapidly report the triage dose
estimates of blind samples and a second one to provide the complete
data including calibration data, and details concerning the technical
performance. The time between the arrival of the samples at the
participating laboratory (courier report) and the return of the dose
estimates of blind samples to the organizer by e-mail was documented.
Further information about each laboratory was collected as follows
using a questionnaire: (a) number of exercises the laboratory had
participated in prior to the NATO exercise; (b) a self assessment of the
laboratory’s proficiency level for each assay; (c) how long each assay
had been established; and (d) used for biodosimetry; (e) level of
priority given to the analysis of the NATO samples during daily
business.
Statistical Methods
The accuracy of reported dose estimates was measured by
calculating the mean of the absolute differences (MAD) of estimated
doses to their corresponding true doses. We then examined whether
information of the questionnaire might contribute to the MAD values
using the Spearman rank correlation test and the Wilcoxon test for a
two-group comparison. Finally, we merged doses into binary
categories reflecting clinically/diagnostically/epidemiologically rele-
vant aspects and assessed the agreement between the true doses and
the reported dose estimates among the binary categories (sensitivity,
specificity, overall accuracy). Those categories were:
 never versus ever single radiation exposure (0 Gy/0.1 Gy) to
avoid clinical resources being occupied by the ‘‘worried-well’’ –
unexposed individuals who are concerned they may have been
exposed,
 marginal versus higher single radiation exposures (0.1 Gy/.0.1
Gy) to distinguish groups such as those who do not need clinical
support from others where deterministic or stochastic effects in
adults might occur or become detectable using epidemiological
methods,
 lower versus medium-high single radiation exposure (1.5 Gy/
.1.5 Gy) to select the group of patients who will probably suffer
from the acute radiation syndrome (ARS) several days after
radiation exposure,
 medium versus high-single radiation exposure (2–4 Gy/4 Gy) for
triage purposes in the case of limited clinical resources.
Sensitivity, specificity and accuracy were assessed on the basis of
the estimated doses and a 2 3 2 table of true positive ¼ TP, true
negative ¼ TN, false positive ¼ FP and false negative ¼ FN was
applied. The corresponding percentages were calculated for accuracy
TABLE 1
Participating Institutions and Their Contributions to the Exercise
Institution
Dicentric
assay
CB
micronucleus
assay
c-H2AX
foci
Gene
expression
Blood cell
counts/ARS
severity
Ghent University, Department of Basic Medical
Sciences, Research group: ‘Radiation and DNA
repair’, Ghent, Belgium
X
Institut de Recherche Biome´dical des Arme´es/
CRSSA, Grenoble, France
X X
Life Technologies, Company, Frankfurt, Germany X
Bundeswehr Institute of Radiobiology, Munich,
Germany
X X X X X
Bundesamt fu¨r Strahlenschutz, Munich, Germany X X X
Qiagen, Company, Hilden X
Health Protection Agency, Centre for Radiation,
Chemical and Environmental Hazards, Chilton,
Didcot, Oxon, UK
X X X X
Basic Medical Sciences, Center for Applied
Nanobioscience and Medicine, College of
Medicine Phoenix, University of Arizona,
Phoenix, AZ
X
DxTerity Diagnostics, Company, Rancho
Dominguez, CA
X
Sezione di Istologia e Biologia e Molecolare,
Centro Studie Ricerche di Sanita’e Veterinaria,
Roma, Italy
X X X X
Defence Research and Development, Ottawa ON,
Canada
X X
6 6 4 8 1
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¼ TP þ TN 3 100/(total), sensitivity ¼ TP 3 100/(TP þ FN) and
specificity ¼ TN3 100/(TNþ FP).
To assess the accuracy of dose estimates based on 20, 30, 40 or 50
metaphase spreads for the DCA and the c-H2AX assays we employed
Spearman’s rank correlation test.
RESULTS
Temperature Profiles
Blood samples were sent to 12 institutions, 11 of which
returned dose estimates (Table 1). Six laboratories per-
formed the DCA and CBMN, four the c-H2AX and eight
the gene expression assay. For the calibration samples (sent
in July) temperatures ranged from 10–188C when using ice
(i.e., gene expression or c-H2AX assays) and were
approximately 208C when sending samples at ambient
temperature (i.e., DCA or CBMN assays). For the blind
samples (sent in September) temperatures remained below
108C when using ice and 18–208C for the transport at
ambient temperature. Film badges recorded no additional
radiation exposure during transport.
Transit and Reporting Times
Transit times of samples were approximately one day
within Europe (The Netherlands: 19.5 h, Belgium/France/
UK: 21 h and Italy: 25 h). We recorded about 1.5 days
transit time for samples sent to the U.S. (west coast: 29–31
h) and Canada (32 h). The reports of all ten dose estimates
were received 7–8 h after arrival of blood samples at the
participants’ laboratories for the c-H2AX and gene
expression assays and after 2.4 and 4 days for the DCA
and CBMN assays, respectively (Fig. 1).
Accuracy of Dose Estimations
Comparison of MAD values per assay revealed that the
DCA delivered the most accurate dose estimates (Fig. 2 and
Table 2). Significant 2–3-fold lower accuracy of the
emerging assays was observed when using the DCA as
the reference assay (Fig. 2 and Table 3). Differences were
less significant when using the CBMN as the reference
assay. However, all assays showed considerable variance in
the accuracy of dose estimates reported by different
laboratories, with approximately a threefold difference
between minimal and maximal MAD values for all assays
(Table 2) which decreased when focusing on the 50th or
25th percentile of contributions, reaching values of 1.2–1.5
for all assays for the 25th percentile. Exclusion of dose
estimates for the 6.4 Gy sample (for which the highest
MAD was recorded) did not significantly change these
results. Importantly, we observed the lowest MAD values
(first number in parenthesis) and lowest numbers of dose
estimates outside the 0.5 Gy interval as recommended for
triage dosimetry (second entry in parenthesis) for DCA
(0.16 Gy/0–6 false dose estimates), followed by CBMN
FIG. 1. Earliest report times for ARS severity score prediction (H-module) or dose estimations using molecular (gene expression or c-H2AX)
or cytogenetic assays (dicentric chromosomal assay and cytokinesis block micronucleus assay).
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FIG. 2. Distributions of mean absolute differences (MAD) in dose estimations reported by each laboratory are
shown for each assay separately. Dotted lines refer to the mean value and straight lines to the median.
TABLE 2
Descriptive Statistics of MAD Values Generated for All Performers, the 50th and 25th Performance Percentile per Assay
Including 6.4 Gy sample Excluding 6.4 Gy sample
DCA CBMN
Gene
expression
c-H2AX
foci DCA CBMN
Gene
expression
c-H2AX
foci
MAD, all performers
n 10 11 8 8 10 11 8 8
Minimum 0.16 0.34 0.34 0.45 0.16 0.20 0.27 0.41
Maximum 0.61 0.76 1.35 1.71 0.52 0.50 1.08 1.26
Mean 0.37 0.51 0.75 0.93 0.32 0.34 0.59 0.77
Median 0.40 0.49 0.65 0.68 0.34 0.33 0.55 0.62
Fold-change 3.9 2.2 3.9 3.8 3.2 2.5 4.0 3.1
Number of dose estimates outside 0.5 Gy 0–6 1–6 1–8 2–8 0–5 0–5 0–7 1–7
MAD, 50th percentile
n 5 6 4 4 5 6 4 4
Minimum 0.16 0.34 0.34 0.45 0.16 0.20 0.27 0.41
Maximum 0.39 0.49 0.54 0.63 0.34 0.37 0.56 0.64
Mean 0.27 0.41 0.48 0.56 0.23 0.26 0.41 0.51
Median 0.24 0.42 0.52 0.59 0.20 0.24 0.40 0.50
Fold-change 2.5 1.4 1.6 1.4 2.1 1.8 2.1 1.5
Number of dose estimates outside 0.5 Gy 0–3 1–3 1–4 2–6 0–2 0–2 0–3 1–5
MAD, 25th percentile
n 3 4 2 2 3 4 2 2
Minimum 0.16 0.34 0.34 0.45 0.16 0.20 0.27 0.41
Maximum 0.24 0.43 0.52 0.59 0.20 0.33 0.36 0.54
Mean 0.19 0.38 0.43 0.52 0.18 0.25 0.31 0.50
Median 0.19 0.38 0.43 0.52 0.17 0.24 0.31 0.50
Fold-change 1.5 1.3 1.5 1.3 1.2 1.6 1.3 1.3
Number of dose estimates outside 0.5 Gy 0–1 1–3 1–3 2–3 0–1 0–2 0–2 1–3
Notes. MAD values are shown with and without the 6.4 Gy sample which lay outside the calibrated range of all assays. The fold-change refers
to the ratio between the maximum relative to the minimum MAD value per assay. For each assay we provide ranges in the number of reported
dose estimates lying outside the recommended 0.5 Gy interval for triage dosimetry.
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(0.34 Gy/1–6 false dose estimates), gene expression (0.34
Gy/1–8 false dose estimates) and c-H2AX assays (0.45 Gy/
2–8 false dose estimates) (Table 2). Both the MAD values
and the number of false dose estimates decreased when the
6.4 Gy sample was excluded from the analysis and/or
contributions were restricted to the 50th or the 25th
percentile.
Assay Performance in a Triage Setting
The main objective of triage in a large-scale incident is to
classify patients depending on their need for acute clinical
intervention, more detailed diagnostic tests or long-term
epidemiological follow-up. To test the performance of the
assays within such a framework, we aggregated dose
estimates into binary categories using corresponding
threshold doses of 4 Gy, 1.5 Gy and 0.1 Gy and determined
the accuracy, sensitivity and specificity of the classifications
performed with the four assays (Table 4). We restricted this
comparison to laboratory contributions with low MAD
values (gene expression and c-H2AX) and manual scoring
procedures (DCA and CBMN) to reflect assay rather than
laboratory performance characteristics. Gene expression and
c-H2AX assays delivered similar results to the CBMN
assay for all binary categories. In comparison to the DCA
assay we observed about 10% lower accuracy and
sensitivity for the higher cut-off levels at 1.5 (c-H2AX)
and 4 Gy (c-H2AX and gene expression).
DISCUSSION
It was the goal of the NATO exercise to compare
laboratories performance in dose assessments using estab-
lished (DCA and CBMN) and emerging assays (gene
expression and c-H2AX) for triage mode biodosimetry.
Surprisingly, all assays showed a similar ;3-fold inter-
laboratory variation in the accuracy of dose estimates. This
finding demonstrates that, in addition to the fixed intrinsic
accuracy of an assay, each assay’s ‘‘real world’’ perfor-
mance also depends very much on the expertise of the
laboratory performing the assay, which may vary signifi-
cantly over time, depending on e.g., staffing and the focus
TABLE 3
Statistical Analysis of MAD Values
Reference, DCA CBMN
Gene
expression
c-H2AX
foci Reference, CBMN DCA
Gene
expression
c-H2AX
foci
All performers All performers
(reference: DCA, n ¼ 10, mean
¼ 0.38, median ¼ 0.40)
(reference: CBMN, n ¼ 11,
mean ¼ 0.49 median ¼ 0.51)
n 11 8 8 n 10 8 8
Test t test Mann
Whitney
t test Test t test Mann
Whitney
t test
Median/mean 0.51 0.65 0.93 Median/mean 0.38 0.65 0.93
Ratio to reference 1.3 1.7 2.5 Ratio to reference 0.7 1.3 1.8
P value 0.04 0.009 0.003 P value 0.04 0.09 0.01
50th percentile 50th percentile
(reference: DCA, n ¼ 5, mean
¼ 0.27, median ¼ 0.24)
(reference: CBMN, n ¼ 6,
Mean ¼ 0.41, median ¼
0.42)
n 6 4 4 n 5 4 4
Test Mann
Whitney
t test t test Test Mann
Whitney
t test t test
Median/mean 0.42 0.48 0.56 Median/mean 0.24 0.48 0.56
Ratio to reference 1.7 1.8 2.1 Ratio to reference 0.6 1.2 1.4
P value 0.03 0.01 0.002 P value 0.03 0.18 0.008
25th percentile 25th percentile
(reference: DCA, n ¼ 3, mean
¼ 0.19)
(reference: CBMN, n ¼ 4,
Mean ¼ 0.38, median ¼
0.38)
n 4 2 2 n 3 2 2
Test t test t test t test Test t test Mann
Whitney
t test
Median/mean 0.38 0.43 0.52 Median/mean 0.19 0.43 0.52
Ratio to reference 2.0 2.2 2.7 Ratio to reference 0.5 1.1 1.4
P value 0.002 0.049 0.012 P value 0.002 0.8 0.1
Notes. MAD values derived from reported dose estimates using DCA or CBMN assays as reference and examining all performers or 50th and
25th percentiles of the other assays. Depending on equality of normal distribution or variance either the t test or the Mann Whitney rank sum test
were applied.
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of the laboratory. In this exercise, the variance in dose
estimate accuracy between laboratories using the same
assay was at least equal or even greater than the variance
between the assays themselves when used by the best
performing laboratories. Results of the questionnaire
confirmed that the variance in accuracy was in part caused
by differences in the experience of laboratories, as
illustrated by the number of previous exercises or the
period for which the assays had been established prior to
this exercise (for details see the four companion articles of
this series). It is well conceivable that it may take years to
accurately perform either established or emerging assays
and it is these skills which affect performance differences,
together with the level of ‘‘maturity’’, i.e., harmonization
and standardization of the assay.
Because of these performance differences we decided to
compare not just all contributions but to also restrict our
analysis to the 50th and 25th performance percentile of
contributions per assay to obtain an unmasked picture of the
intrinsic biological and methodological differences between
established and emerging assays. Our data suggest a
significant 2–3-fold higher accuracy of dose estimates
generated by the DCA assay in comparison to the other
assays including the CBMN assay. When using the CBMN
assay as the reference this advantage in accuracy becomes
insignificant for the gene expression assay and borderline
significant for the c-H2AX assay. Concomitantly, we
observed fewer reported dose estimates outside the 0.5 Gy
interval for the DCA assay compared to the other assays.
However, this effect became less significant after restricting
the analysis to the 25th performance percentile and
excluding the 6.4 Gy sample (Table 2). Hence, even at
this early stage, emerging assays under optimal conditions
provide dose estimates with an accuracy as good as the
CBMN assay, though they are 2–3 times less precise than
the DCA assay.
All assays showed an upper limit of applicability below
the highest blind dose of 6.4 Gy, which was systematically
underestimated by all assays. While it is known that the
established cytogenetic assays perform less well at very
high doses, one can speculate that the lack of calibration
data above 5 Gy is the primary reason for the poor
performance of the assays. This finding therefore underlines
the importance of relying on the assays only within the
calibrated dose range, as extrapolation may not take into
account deviations in the dose response for the assay. In the
case of the cytogenetic methods such deviations may be
associated with the prolonged cell cycle delay that is
observed at high doses (3), whereas for gene expression and
c-H2AX assays saturation effects in gene transcription and
foci scoring, respectively (22, 25), may be responsible for a
leveling off towards high doses that would be unaccounted
for in the calibration curve with its upper limit of 5 Gy. Yet,
removing the 6.4 Gy point from the analysis had no impact
on fold-change differences between assays, since it affected
all assays similarly.
From the dosimetry point of view and for long-term
epidemiological follow-up it is desirable to estimate doses
as accurately as possible. From the clinical point of view
dose ranges often provide sufficient information to address
urgent clinical or diagnostic needs. This is why we divided
the 10 samples into binary categories as already described.
In this framework, the emerging assays performed as well as
the CBMN assay and almost as well as the DCA assay,
despite their comparatively low level of validation,
harmonization and standardization.
Within this exercise one institution also employed a
software tool for prediction of effects (hematological
syndrome of the acute radiation syndrome, ARS), but not
dose. Blood cell counts (BCC) from radiation accident
victims were correlated with the severity of the clinical
outcome using the database SEARCH (System for Evalu-
ation and Archiving of Radiation Accidents based on Case
Histories) (26, 27). With logistic regression we developed
models to predict the ARS severity based on BCC. The
models were converted into Excel and after entering BCCs
by the user, these algorithms automatically generate
predictions on diagnosis (ARS severity) and recommend
treatment options. BCCs were chosen from real radiation
accident cases and we compared the accuracy of ARS
predictions based on BCCs taken on day 1 or on days 1 and
TABLE 4
Accuracy, Sensitivity and Specificity of Triage Classifications
are Shown for Each Assay after Aggregation of Dose
Estimates into Binary Categories
Overall
Assay Accuracy Sensitivity Specificity
Never/ever radiation exposure
DCA 91.5% 94.3% 66.7%
CBMN 90.0% 97.2% 25.0%
Gene expression 92.5% 94.4% 75.0%
c-H2AX foci 94.0% 100.0% 40.0%
0.1 vs. .0.1 Gy radiation exposure
DCA 91.5% 100.0% 58.3%
CBMN 92.5% 100.0% 62.5%
Gene expression 97.5% 100.0% 87.5.0%
c-H2AX foci 88.0% 100.0% 40.0%
,1.5 vs. 1.5 Gy radiation exposure
DCA 94.9% 100.0% 87.5%
CBMN 95.0% 100.0% 87.5%
Gene expression 95.0% 100.0% 87.5%
c-H2AX foci 86.0% 96.7% 70.0%
2–4 vs. 4 Gy radiation exposure
DCA 97.1% 90.9% 100.0%
CBMN 83.3% 50.0% 100.0%
Gene expression 83.3% 75.0% 87.5%
c-H2AX foci 86.7% 60.0% 100.0%
Note. This comparison focuses on laboratory contributions with
low-MAD values (gene expression and c-H2AX) and manual scoring
procedures (DCA and CBMN) to reflect the intrinsic assay
characteristics and to a lesser extent performance specific differences.
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2 or on the first 3 consecutive days after radiation exposure.
Irrespective of time we received correct ARS categories in 8
of our 10 BCCs. These 80% correctly predicted ARS
categories were detected even within a few hours after
exposure, the time it takes to generate the BCC using the
widely available automated blood cell counters in hospitals.
The accuracy of this early estimate taken shortly after
exposure can be validated using a sequential diagnosis with
BCC performed on the next 2–3 days after exposure. Hence,
this tool adds early additional information for clinical
diagnostic and therapeutic decision-making, but it certainly
has to be combined with other assays to further reduce the
false categorization.
This exercise provided additional experiences and
insights, which could be covered under the title ‘‘lessons
learned’’. These included one failed sample delivery
because reception staff had not been informed; breakdown
of the automated metaphase finder – DCA measurements
were done manually instead; difficulties to find 50 scorable
cells for the c-H2AX assay when using only 1 ml blood;
delays in reporting dose estimates caused by a lack of
automation in dose calculations from raw data; delays
caused by strict minimum staffing rules when performing
assays; reduction of temperature variations during sample
transport by additional wrapping in aluminum foil;
successful exercise organization using email only.
The exposure scenario used for this exercise has a number
of limitations. We deliberately restricted all measurements to
blood samples taken from only one individual to focus on
methodological variance and to exclude interindividual
variance which has been reported for several of the assays
(20, 28). For the same reason we varied only the dose and did
not simulate nonuniform radiation exposures. It is important
to note that results may well differ considerably in the case of
nonuniform exposures. Only the DCA and c-H2AX assay
but not the other methods have been formally shown to be
able to detect and quantify nonuniform exposures in certain
scenarios, based on the distribution of dicentrics or foci,
respectively, among analyzed cells (3, 25, 29, 30). Even
then, the low number of cells scored in triage mode may pose
difficulties in the case of highly nonuniform exposures (31).
More data and better statistical methods are needed to fully
understand the impact of nonuniform exposures on biolog-
ical dose estimates and associated uncertainties (32).
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